AzTrials
AzTrials

To Assess the Bone Healing in Fracture Mandible DefectsPhase 2/3NCT05480631

COMPARATIVE ANALYSIS OF INNOVATIVE BONE HEALING TECHNIQUES

A Phase 2/3 study testing autograft, autograft with addition of concenterated growth factor and xenograft with concentrated growth factor in people with To Assess the Bone Healing in Fracture Mandible Defects, run by Dow University of Health Sciences at 1 site in Pakistan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

the study intends to observe the outcome of interventions (concentrated growth factor with autograft and xenograft) used to expedite bone healing and adaptation with minimal side effects. Three different modalities are being used to bridge the mandibular fracture defects (>5mm-<5cm). Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
What is being tested?
autograft, autograft with addition of concenterated growth factor and xenograft with concentrated growth factor
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 sitePakistan
Study dates
17 Dec 2020to 20 Jul 2022
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Male/female
  • Mandible fracture (symphysis, parasymphysis, and body)
  • Defect gap of bone >5mm and <5cm.
  • Non-union fracture. (Fracture that does not heal after 8 weeks of treatment is known as a non-union)
  • Mal-union (when the fracture segments are not in anatomical alignment and heals in that way forming a bone between displaced segments)
  • Delayed union (Fracture which takes greater than 5 weeks to repair is a delayed union)

Who cannot join

  • Systemic disease involvement such as diabetes mellitus.
  • Bone-related disorders such as osteoarthritis,
  • Undergoing Chemo and or radiotherapy
  • Gunshot trauma with more than 5cm bone defect
  • Fracture with open wounds

Trial locations and contacts

1 site in 1 country.

Pakistan1 site, 1 recruiting
  • Dow University of health sciences

    Karachi, Sindh, 74200

    Dr.Abdul hafeez shaikh, FCPS, +923332247325, drabdulhafeezshaikh@hotmail.com

    dr. shaheen Ahmed, FCPS, +923212275892, drshaheenahm@gmail.com

    Recruiting

Other trials in Pakistan

About this study

Official title: COMPARATIVE ANALYSIS OF INNOVATIVE BONE HEALING TECHNIQUES IN MANDIBLE BONE DEFECTS

the study intends to observe the outcome of interventions (concentrated growth factor with autograft and xenograft) used to expedite bone healing and adaptation with minimal side effects. Three different modalities are being used to bridge the mandibular fracture defects (>5mm-<5cm). Those modalities include group A- autograft, group B-autograft with concentrated growth factor, and group C- xenograft with concentrated growth factor. the outcomes are measured in terms of acquired bone density (Hounsfield unit) that is obtained at the 4th and 6th month post-operatively via cone-beam computed tomography.

Read the detailed description

Study Design:

Randomized clinical trial

Study Population:

The study will be conducted on patients with mandible fracture defects, exclusively of defect sizes ranging from 5mm to 5cm.

Study Settings:

Department of Oral and Maxillofacial Surgery of

  • Dr.Ruth K.M PFAU/ Civil Hospital Karachi
  • Ojha Hospital and associated Out Patient Departments. The study will be conducted on patients with mandible fracture defects, exclusively of defect sizes ranging from 5mm to 5cm.

Sampling Technique:

  • Non-probability purposive sampling was done in participants fulfilling the inclusion criteria of the study. The diagnosis was made by evaluation of pre-operative Orthopantamamogram along with clinical examination. The defect of the fractured bone was measured from Orthopantomagram then the patient's general physical examination and detailed history were taken. Written and verbal consent was taken by informing the patient regarding all the possible favorable and unfavorable outcomes of the study. Once the consent was taken, Proforma was filled by the principal investigator followed by randomization. Participants in then allocated to any of the three groups that were disclosed via envelope. A total of 60 envelopes were made in three groups that are 20 out of which were of group A receiving autograft as a reconstruction option. Other 20 envelopes were of group B receiving autograft with concentrated growth factor whilst 20 envelopes were of group C receiving xenograft with concentrated growth factor. Participants were asked to randomly pick any of the envelope disclosing the group they were allocated to.

Sample Size A total of 60 subjects were recruited and divided into 3 groups, 20 subjects in each group sample size was calculated using open epi online software.

3.6 Study Duration 2 years after synopsis approval. Inclusion Criteria

  • Aged 18-40
  • Male/female
  • Mandible fracture (symphysis, parasymphysis, and body)
  • Defect gap of bone >5mm and <5cm.
  • Non-union fracture. (Fracture that does not heal after 8 weeks of treatment is known as a non-union)
  • Mal-union (when the fracture segments are not in anatomical alignment and heals in that way forming a bone between displaced segments)
  • Delayed union (Fracture which takes greater than 5 weeks to repair is a delayed union) Exclusion Criteria
  • Systemic disease involvement such as diabetes mellitus.
  • Bone-related disorders such as osteoarthritis,
  • Undergoing Chemo and or radiotherapy
  • Gunshot trauma with more than 5cm bone defect
  • Fracture with open wounds Study Parameters Study Variables
  • Bone healing
  • Concentrated Growth Factor
  • Autograft
  • Bovine xenograft Outcome Variables
  • Bone healing (bone density) Exposure Variables
  • Concentrated Growth Factor
  • Autograft
  • Bovine xenograft

Ethical Considerations:

Patient's voluntary participation was ensured for this study with their informed verbal and written consent. The information was kept confidential. Only the authorized principal and/or co-investigators were allowed to access the patient's data. Patients were allowed to withdraw from the study at any given point and were also provided with the contact information of concerned authorities in case of communicating their issues regarding the study.

Ethical approval for the study was taken from DUHS reference number: Institutional Review Board-1835/Approval/2020

Data Collection Procedure:

Once the definitive diagnosis is made and the participant is recruited to the allocated group after randomization, consent is taken and the participant's detailed history Proforma is filled. Then the fracture is assessed over a radiograph OPG (Orthopantomogram) categorizing it into either malunion, non-union, or delayed union.

Preparation of concentrated growth factor:

concentrated growth factor was prepared in a centrifuge machine by following standard protocol, machine that was used was product name: Benchtop PRP, PRF, concentrated growth factor, and serial no XX2201XF008. The autologous blood of around 10cc was taken in an empty red top vacutainer tube and is directly placed in a centrifuge machine with a contralateral tube filled with water for balancing purposes. The drawn blood was immediately transferred to a centrifuge machine to avoid clotting. The pre-setting concentrated growth factor option was selected that has an acceleration cycle of 30 sec followed by 2min revolutions at 2700rpm, then followed by 4min of revolutions at 2400rpm, then 4min at 2700rpm leading to 3 min at 3000rpm, and after which the deceleration phase started that lasts for 36 seconds.

Surgical procedure:

After taking Anesthesia Administration Assembly measures, under general anesthesia opting for adequate exposure and scrubbing was undertaken. Local anesthesia containing xylocaine 2% with adrenaline 1:200,000, was injected in the buccal sulcus of the site of fracture. An intra-oral vestibular incision was then given to raise a full-thickness flap in order to expose the fracture adequately; the mental nerve is located and secured alongside bleeding is controlled to assess the fracture site. After removing granulation tissue and mal-aligned bony fragments (in case of mal-union fracture) the size of the defect was gauged using a millimeter scale. Occlusion is restored and bony fragments are held in the best possible anatomic location. Titanium mini-plates are held in place for fixation of fracture whilst the defect is restored and filled with either autograft, autograft with concentrated growth factor, or bovine xenograft with concentrated growth factor. Once the graft is stabilized soft tissue is re-approximated using Vicryl 3.0 sutures.

Surgical procedure for harvesting autograft from intraoral site In cases where autograft was intended to utilize, a pre-operative evaluation was done via assessing the radiograph and palpation. The inferior alveolar nerve block was given then the incision was given at the buccal site just medial to the external oblique ridge from there the extension of the incision is made towards the retromolar pad area. The incision ascending towards Ramal height was kept at the level of the occlusal plane of the mandibular second molar tooth to avoid exposure to the buccal fat pad or injury to the buccal artery. A full-thickness flap was raised above the external oblique ridge and osteotomy was done following 1/3rd thickness from the buccal cortical aspect of the ramus. The desired chunk of not more than 1cm was taken. Osteotomy cuts are inferior ramus cut, and superior ramus cut whilst anterior body cut and inferior to external oblique ridge cut was made with a bur. The anterior cut was kept behind the body and the superior cut was kept below the level of the coronoid, however, this site can provide up to 40mm long grafts but the required donor site defect was not more than 9mm maximum in all groups. Conventionally ramus can provide up to half of its thickness graft in situations where the only graft is intended whilst this study took only 1/3 of the thickness as per requirement. The harvested bone in group "A" participants is kept in place in the defect and secured with mini-screws.

Mechanical Mixing Of concentrated growth facto with Bone Particulates The autologous bone is crushed and mixed with concentrated growth facto via mechanical means similarly, bone particulate of Xeno-graft are also integrated with concentrated growth facto to form a consistent pliable buffy tissue that can be manipulated according to defect size.

Evaluation over Cone Beam Computed Tomography:

Post-operatively Cone Beam Computed Tomography was conducted in all patients in the 4th and 6th months; the machine used was of brand Ville system medical model Uni-Tech Scientific series 16020502. The Cone Beam Computed Tomography for evaluation and tabulation of Bone Mineral Density from the region of interest that is occlusal to the fracture defect was done by assessing the grey level on Cone Beam Computed Tomography by a radiology specialist

Being tested
autograft, autograft with addition of concenterated growth factor, xenograft with concentrated growth factor
Keywords
Concentrated growth factor, bone density, mandible fracture
Medical subject headings
Mandibular Fractures

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • autograftProcedure or surgery

    autologous bone placed in the defect and then be secured with mini-screws to fill the fracture defect gap

  • autograft with addition of concenterated growth factorProcedure or surgery

    the bone particulate harvested from the donor site will then be mixed with concentrated growth factor to bridge the fracture defect.

  • xenograft with concentrated growth factorProcedure or surgery

    xenogenic bovine bone particulate mixed with platelet-derived concentrated growth factor to be held in place of fracture defect site.

Study groups in NCT05480631
Study groupRoleWhat they receive
Group AActive comparatorgroup A- autograft
Receives: Procedure: autograft
group BExperimentalgroup B- concentrated growth factor with autograft
Receives: Procedure: autograft with addition of concenterated growth factor
Group CExperimentalgroup C- concentrated growth factor with xenograft
Receives: Procedure: xenograft with concentrated growth factor

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. bone density

    acquired bone density in region of interest via cone beam computed tomography expressed in Hounsfield units

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jul 2022
  2. Study start17 Dec 2020
  3. Primary completion20 Jul 2022 (estimated)
  4. Study completion20 Jul 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05480631
Sponsor's protocol ID
IRB-1835/DUHS/approval/2020
Status last verified
Jul 2022
First submitted
27 Jul 2022
Last updated
29 Jul 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing autograft, autograft with addition of concenterated growth factor and xenograft with concentrated growth factor in people with To Assess the Bone Healing in Fracture Mandible Defects, run by Dow University of Health Sciences at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

bone density (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in